A look into stent-related thrombus-burden: Bivalirudin versus heparin
Editorial commentary published in Catheterization and Cardiovascular Interventions (2020)
Abstract
Use of optical coherence tomography (OCT) adds an assessment of thrombus burden remaining on stents after PCI for acute coronary syndromes. Potential variations in stent-related thrombus burden can be documented by OCT as a function of peri-procedural pharmacology supporting the use of OCT in future hypothesis testing. Bivalirudin remains a reliable and expensive alternative to heparin in cases of HIT or patients at high bleeding risk during transfemoral PCI.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Editorial commentary discussing OCT-based assessment of residual stent-thrombus burden after PCI with bivalirudin vs heparin, supporting bivalirudin as an alternative in HIT and high-bleed-risk populations.
Why This Matters for Hirudotherapy
This article discusses optical coherence tomography (OCT) assessment of thrombus burden remaining on stents after percutaneous coronary intervention for acute coronary syndromes, noting that variations in stent-related thrombus burden can be documented as a function of peri-procedural pharmacology. It states that bivalirudin remains a reliable and expensive alternative to heparin in cases of heparin-induced thrombocytopenia or high bleeding risk during transfemoral PCI. Its relevance to ASH is indirect at most: the abstract does not describe bivalirudin as leech-derived, synthetic, or modeled on hirudin, and does not discuss leeches, hirudotherapy, or the leech secretome. The connection to ASH is therefore limited and not established by the abstract itself.
Citation
A look into stent-related thrombus-burden: Bivalirudin versus heparin.
Rajagopalan P et al. · Catheterization and Cardiovascular Interventions, 2020
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026